AGN-229666 for the Treatment of Allergic Conjunctivitis

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.

Phase 2

Allergan